Pathophysiology and Etiology of Heart Failure

Cardiology Clinics

Volumn 32, Issue 1, 2014, Pages 9-19

  Johnson, Frances L ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

Diagnosis; Etiology; Heart failure; Pathophysiology

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; CALCIUM; CISPLATIN DERIVATIVE; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR 2 ANTIBODY; INOTROPIC AGENT; MONOCLONAL ANTIBODY; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

APOPTOSIS; CALCIUM CELL LEVEL; CARDIOMYOPATHY; CARDIOTOXICITY; CARDIOVASCULAR MAGNETIC RESONANCE; CARDITIS; COMORBIDITY; COMPUTER ASSISTED TOMOGRAPHY; CONGESTIVE CARDIOMYOPATHY; CONSERVATIVE TREATMENT; DIAGNOSTIC TEST; DISEASE ASSOCIATION; DISEASE COURSE; EXTRACELLULAR MATRIX; FAMILIAL CARDIOMYOPATHY; FAMILIAL DISEASE; GENE MUTATION; HEALTH CARE QUALITY; HEART FAILURE; HEART HEMODYNAMICS; HEART HYPERTROPHY; HEART INJURY; HEART MUSCLE FIBROSIS; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; INFILTRATIVE CARDIOMYOPATHY; INFLAMMATORY CARDIOMYOPATHY; ISCHEMIC CARDIOMYOPATHY; MECHANICAL STRESS; MORTALITY; MULTIDETECTOR COMPUTED TOMOGRAPHY; NEUROENDOCRINE DISEASE; PATHOPHYSIOLOGY; PATIENT ASSESSMENT; PATIENT CODING; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; STANDARDIZATION; TOXIC CARDIOMYOPATHY; TRANSTHORACIC ECHOCARDIOGRAPHY; VALVULAR CARDIOMYOPATHY; VALVULAR HEART DISEASE;

DIAGNOSIS; ETIOLOGY; HEART FAILURE; PATHOPHYSIOLOGY;

APOPTOSIS; CALCIUM CHANNELS; CARDIAC IMAGING TECHNIQUES; CARDIOMEGALY; CARDIOMYOPATHIES; DIAGNOSIS, DIFFERENTIAL; HEART FAILURE; HEART VALVE DISEASES; HEMODYNAMICS; HUMANS; HYPERTENSION; MUTATION; MYOCARDIAL ISCHEMIA; NEUROTRANSMITTER AGENTS; VENTRICULAR REMODELING;

EID: 84888227537     PISSN: 07338651     EISSN: 15582264     Source Type: Journal    
DOI: 10.1016/j.ccl.2013.09.015     Document Type: Review

References (63)

1. Owan T.E., Hodge D.O., Herges R.M., et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. NEngl J Med 2006, 355(3):251-259.
2. Alagiakrishnan K., Banach M., Jones L.G., et al. Update on diastolic heart failure or heart failure with preserved ejection fraction in the older adults. Ann Med 2013, 45:37-50.
3. Sarnoff S.J., Berglund E. Ventricular function: I. Starling's law of the heart studied by means of simultaneous right and left ventricular function curves in the dog. Circulation 1954, 9(5):706-718.
4. Holubarsch C., Ruf T., Goldstein D.J., et al. Existence of the Frank-Starling mechanism in the failing human heart: investigations on the organ, tissue, and sarcomere levels. Circulation 1996, 94(4):683-689.
5. Yancy C.W., Jessup M., Bozkurt B., et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. Int J Cardiol 2013, 62(6):e147-e239.
6. van der Zwaan H.B., Geleijnse M.L., McGhie J.S., et al. Right ventricular quantification in clinical practice: two-dimensional vs. three-dimensional echocardiography compared with cardiac magnetic resonance imaging. Eur J Echocardiogr 2011, 12(9):656-664.
7. Pennell D.J. Cardiovascular magnetic resonance. Circulation 2010, 121(5):692-705.
8. Kim R.J., Wu E.E., Rafael A.A., et al. The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. NEngl J Med 2000, 343(20):1445-1453.
9. McCrohon J.A., Moon J.C., Prasad S.K., et al. Differentiation of heart failure related to dilated cardiomyopathy and coronary artery disease using gadolinium-enhanced cardiovascular magnetic resonance. Circulation 2003, 108(1):54-59.
10. Rajappan K., Bellenger N.G., Anderson L., et al. The role of cardiovascular magnetic resonance in heart failure. Eur J Heart Fail 2000, 2(3):241-252.
11. Reiter T.T., Ritter O.O., Prince M.R., et al. Minimizing risk of nephrogenic systemic fibrosis in cardiovascular magnetic resonance. JCardiovasc Magn Reson 2012, 14:31.
12. Arrighi J.A., Dilsizian V.V. Multimodality imaging for assessment of myocardial viability: nuclear, echocardiography, MR, and CT. Curr Cardiol Rep 2012, 14(2):234-243.
13. Lin F.Y., Min J.K. Assessment of cardiac volumes by multidetector computed tomography. JCardiovasc Comput Tomogr 2008, 2(4):256-262.
14. Mangalat D., Kalogeropoulos A., Georgiopoulou V., et al. Value of cardiac CT in patients with heart failure. Curr Cardiovasc Imaging Rep 2009, 2(6):410-417.
15. Andreini D., Pontone G., Bartorelli A.L., et al. Sixty-four-slice multidetector computed tomography: an accurate imaging modality for the evaluation of coronary arteries in dilated cardiomyopathy of unknown etiology. Circ Cardiovasc Imaging 2009, 2(3):199-205.
16. Allen L.A., Rogers J.G., Warnica J.W., et al. High mortality without escape: the registry of heart failure patients receiving pulmonary artery catheters without randomization. JCard Fail 2008, 14(8):661-669.
17. Schrier R.W., Abraham W.T. Hormones and hemodynamics in heart failure. NEngl J Med 1999, 341(8):577-585.
18. Ky B.B., French B.B., Levy W.C., et al. Multiple biomarkers for risk prediction in chronic heart failure. Circ Heart Fail 2012, 5(2):183-190.
19. Morrison L.K., Harrison A., Krishnaswamy P., et al. Utility of a rapid B-natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea. JAm Coll Cardiol 2002, 39(2):202-209.
20. Hare J.M., Walford G.D., Hruban R.H., et al. Ischemic cardiomyopathy: endomyocardial biopsy and ventriculographic evaluation of patients with congestive failure, dilated cardiomyopathy and coronary artery disease. JAm Coll Cardiol 1992, 20(6):1318-1325.
21. Rahimtoola S.H., Dilsizian V., Kramer C.M., et al. Chronic ischemic left ventricular dysfunction. JACC Cardiovasc Imaging 2008, 1(4):536-555.
22. Meluzín J., Černý J., Groch L., et al. Prognostic importance of the quantification of myocardial viability in revascularized patients with coronary artery disease and moderate-to-severe left ventricular dysfunction. Int J Cardiol 2003, 90(1):23-31.
23. Pasquet A., Lauer M.S., Williams M.J., et al. Prediction of global left ventricular function after bypass surgery in patients with severe left ventricular dysfunction. Impact of pre-operative myocardial function, perfusion, and metabolism. Eur Heart J 2000, 21(2):125-136.
24. Buckley O., Di Carli M. Predicting benefit from revascularization in patients with ischemic heart failure: imaging of myocardial ischemia and viability. Circulation 2011, 123(4):444-450.
25. Allman K.C., Shaw L.J., Hachamovitch R., et al. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis. JAm Coll Cardiol 2002, 39(7):1151-1158.
26. Marwick T.H., Zuchowski C., Lauer M.S., et al. Functional status and quality of life in patients with heart failure undergoing coronary bypass surgery after assessment of myocardial viability. JAm Coll Cardiol 1999, 33(3):750-758.
27. Braunwald E. Heart failure. Heart Failure 2013, 1:1-20.
28. Gandhi M.S., Kamalov G., Shahbaz A.U., et al. Cellular and molecular pathways to myocardial necrosis and replacement fibrosis. Heart Fail Rev 2011, 16(1):23-34.
29. Mann D.L. Heart failure: a companion to Braunwald's heart disease 2010, Elsevier Saunders, St. Louis (MO).
30. Deschamps A.M., Spinale F.G. Pathways of matrix metalloproteinase induction in heart failure: bioactive molecules and transcriptional regulation. Cardiovasc Res 2006, 69(3):666-676.
31. Yan A.T., Yan R.T., Spinale F.G., et al. Relationships between plasma levels of matrix metalloproteinases and neurohormonal profile in patients with heart failure. Eur J Heart Fail 2008, 10(2):125-128.
32. Li Y.Y., McTiernan C.F., Feldman A.M. Interplay of matrix metalloproteinases, tissue inhibitors of metalloproteinases and their regulators in cardiac matrix remodeling. Cardiovasc Res 2000, 46(2):214-224.
33. Narula J.J., Haider N.N., Virmani R.R., et al. Apoptosis in myocytes in end-stage heart failure. NEngl J Med 1996, 335(16):1182-1189.
34. Fisher S.A., Langille B.L., Srivastava D. Apoptosis during cardiovascular development. Circ Res 2000, 87(10):856-864.
35. Haudek S.B., Taffet G.E., Schneider M.D., et al. TNF provokes cardiomyocyte apoptosis and cardiac remodeling through activation of multiple cell death pathways. JClin Invest 2007, 117(9):2692-2701.
36. 2+ handling in heart failure. Circ Res 2013, 113(6):690-708.
37. Papolos A., Frishman W.H. Sarcoendoplasmic reticulum calcium transport ATPase 2a: a potential gene therapy target in heart failure. Cardiol Rev 2013, 21:151-154.
38. Bers D.M. CaMKII inhibition in heart failure makes jump to human. Circ Res 2010, 107(9):1044-1046.
39. Richardson P.P., McKenna W.W., Bristow M.M., et al. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of Cardiomyopathies. Circulation 1996, 93(5):841-842.
40. Hershberger R.E., Siegfried J.D. Update 2011: clinical and genetic issues in familial dilated cardiomyopathy. JAm Coll Cardiol 2011, 57(16):1641-1649.
41. Ackerman M.J., Priori S.G., Willems S., et al. HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). Heart Rhythm 2011, 8:1308-1339.
42. Miller E.M., Wang Y., Ware S.M. Uptake of cardiac screening and genetic testing among hypertrophic and dilated cardiomyopathy families. JGenet Couns 2013, 22(2):258-267.
43. Hershberger R.E., Lindenfeld J., Mestroni L., et al. Genetic evaluation of cardiomyopathy-a Heart Failure Society of America practice guideline. JCard Fail 2009, 15(2):83-97.
44. West R., Ellis G., Brooks N., et al. Complications of diagnostic cardiac catheterisation: results from a confidential inquiry into cardiac catheter complications. Heart 2006, 92(6):810-814.
45. Lindenfeld J., Albert N.M., Boehmer J.P., et al. Executive summary: HFSA 2010 comprehensive heart failure practice guideline. JCard Fail 2010, 16(6):475-539.
46. Ten Kate G., Caliskan K., Dedic A., et al. Computed tomography coronary imaging as a gatekeeper for invasive coronary angiography in patients with newly diagnosed heart failure of unknown aetiology. Eur J Heart Fail 2013, 15(9):1028-1034.
47. Assomull R.G., Shakespeare C., Kalra P.R., et al. Role of cardiovascular magnetic resonance as a gatekeeper to invasive coronary angiography in patients presenting with heart failure of unknown etiology. Circulation 2011, 124(12):1351-1360.
48. Chen J., Einstein A.J., Fazel R., et al. Cumulative exposure to ionizing radiation from diagnostic and therapeutic cardiac imaging procedures: a population-based analysis. JAm Coll Cardiol 2010, 56(9):702-711.
49. Gerber T.C., Carr J.J., Arai A.E., et al. Ionizing radiation in cardiac imaging: a science advisory from the American Heart Association Committee on Cardiac Imaging of the Council on Clinical Cardiology and Committee on Cardiovascular Imaging and Intervention of the Council on Cardiovascular Radiology and Intervention. Circulation 2009, 119(7):1056-1065.
50. Laskey W.K., Feinendegen L.E., Neumann R.D., et al. Low-level ionizing radiation from noninvasive cardiac imaging: can we extrapolate estimated risks from epidemiologic data to the clinical setting?. JACC Cardiovasc Imaging 2010, 3(5):517-524.
51. Lloyd-Jones D., Adams R., Carnethon M., et al. Heart disease and stroke statistics-2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2009, 119(3):480-486.
52. Ward C. Clinical significance of the bicuspid aortic valve. Heart 2000, 83(1):81-85.
53. Guy T.S., Hill A.C. Mitral valve prolapse. Annu Rev Med 2012, 63:277-292.
54. Lindman B.R., Bonow R.O., Otto C.M. Current management of calcific aortic stenosis. Circ Res 2013, 113(2):223-237.
55. Hershberger R.E., Cowan J., Morales A., et al. Progress with genetic cardiomyopathies: screening, counseling, and testing in dilated, hypertrophic, and arrhythmogenic right ventricular dysplasia/cardiomyopathy. Circ Heart Fail 2009, 2(3):253-261.
56. Ackerman M.J., Mohler P.J. Defining a new paradigm for human arrhythmia syndromes: phenotypic manifestations of gene mutations in ion channel- and transporter-associated proteins. Circ Res 2010, 107(4):457-465.
57. Kühl U.U., Pauschinger M.M., Seeberg B.B., et al. Viral persistence in the myocardium is associated with progressive cardiac dysfunction. Circulation 2005, 112(13):1965-1970.
58. Blauwet L.A., Cooper L.T. Myocarditis. Prog Cardiovasc Dis 2010, 52(4):274-288.
59. Caforio A.L., Pankuweit S., Arbustini E., et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2013, 34(33):2636-2648.
60. Frustaci A., Chimenti C., Calabrese F., et al. Immunosuppressive therapy for active lymphocytic myocarditis: virological and immunologic profile of responders versus nonresponders. Circulation 2003, 107(6):857-863.
61. Cooper L.T., Hare J.M., Tazelaar H.D., et al. Usefulness of immunosuppression for giant cell myocarditis. Am J Cardiol 2008, 102(11):1535-1539.
62. Cooper L.T., Baughman K.L., Feldman A.M., et al. The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. Circulation 2007, 116(19):2216-2233.
63. Berardi R., Caramanti M., Savini A., et al. State of the art for cardiotoxicity due to chemotherapy and to targeted therapies: a literature review. Crit Rev Oncol Hematol 2013, 88(1):75-86.